Friday, September 11

Leave a little sharper than you arrived.

News, calculators, learning modules, conference recaps, and daily puzzles. Pick any one, and you’re a little further along than you were.

Today’s puzzle

Medscape · 1 min

FDA greenlights sevabertinib as first-line treatment for HER2-mutated lung cancer

The FDA has granted accelerated approval to sevabertinib (Hyrnuo) as a first-line treatment for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) tyrosine kinase domain activating mutations. The decision was based on the SOHO-01 trial, where 75% of previously untreated patients responded to the oral HER2 inhibitor. It's only the second drug approved in the US for this specific indication.

TCTMD · 1 min

New siRNA therapy slashes triglycerides and pancreatitis risk in severe hypertriglyceridemia

Medscape · 1 min

Once-weekly IcoSema combo outperforms daily insulin glargine in type 2 diabetes

Cancer Therapy Advisor · 1 min

FDA approves camizestrant for ESR1-mutated advanced breast cancer — a first for ctDNA-guided treatment switching

Everything on Curie.MD

NeurologyCoursesLearn what’s new in your field, a few minutes at a time.Start learning NeurologyConferencesEvery major conference, filtered to what matters for your practice.See the calendar CardiologyCalculatorsEnter the case once. See every relevant score, side by side.Open a calculator All fieldsGamesThree new clinical puzzles every morning.Play today

Get Curie’s Weekly Dose

What changed in clinical practice, policy, and coverage, and what it means for your patients.

Subscribe free Free. Weekly. Unsubscribe anytime.